MA29020B1 - Composition contenant une vlp et un peptide amyloide beta - Google Patents
Composition contenant une vlp et un peptide amyloide betaInfo
- Publication number
- MA29020B1 MA29020B1 MA29899A MA29899A MA29020B1 MA 29020 B1 MA29020 B1 MA 29020B1 MA 29899 A MA29899 A MA 29899A MA 29899 A MA29899 A MA 29899A MA 29020 B1 MA29020 B1 MA 29020B1
- Authority
- MA
- Morocco
- Prior art keywords
- composition containing
- amyloid peptide
- beta amyloid
- containing vlp
- vlp
- Prior art date
Links
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0424563A GB0424563D0 (en) | 2004-11-05 | 2004-11-05 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA29020B1 true MA29020B1 (fr) | 2007-11-01 |
Family
ID=33523293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA29899A MA29020B1 (fr) | 2004-11-05 | 2007-05-14 | Composition contenant une vlp et un peptide amyloide beta |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US7867499B2 (enExample) |
| EP (2) | EP1812050A1 (enExample) |
| JP (2) | JP2008515954A (enExample) |
| KR (1) | KR20070073882A (enExample) |
| CN (1) | CN101048174A (enExample) |
| AR (1) | AR054092A1 (enExample) |
| AU (2) | AU2005300692A1 (enExample) |
| BR (1) | BRPI0517682A (enExample) |
| CA (1) | CA2581300A1 (enExample) |
| EC (1) | ECSP077415A (enExample) |
| GB (1) | GB0424563D0 (enExample) |
| GT (1) | GT200500313A (enExample) |
| IL (1) | IL182692A (enExample) |
| MA (1) | MA29020B1 (enExample) |
| MX (1) | MX2007005430A (enExample) |
| MY (1) | MY148584A (enExample) |
| NO (1) | NO20072743L (enExample) |
| NZ (1) | NZ583688A (enExample) |
| PE (1) | PE20061047A1 (enExample) |
| RU (1) | RU2415677C2 (enExample) |
| SG (1) | SG170646A1 (enExample) |
| TN (1) | TNSN07166A1 (enExample) |
| TW (1) | TWI380825B (enExample) |
| WO (1) | WO2006048295A1 (enExample) |
| ZA (1) | ZA200702369B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0424563D0 (en) | 2004-11-05 | 2004-12-08 | Novartis Ag | Organic compounds |
| TW201618806A (zh) * | 2010-03-29 | 2016-06-01 | 諾華公司 | 有機化合物之組合物 |
| AU2020348947B2 (en) | 2019-09-16 | 2025-11-27 | Amgen Inc. | Method for external sterilization of drug delivery device |
| CA3208643A1 (en) | 2021-01-18 | 2022-07-21 | Conserv Bioscience Limited | Coronavirus immunogenic compositions, methods and uses thereof |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0038154B1 (en) | 1980-04-15 | 1983-09-21 | Beecham Group Plc | Allergens modified with polysarcosines |
| US5204096A (en) | 1984-03-07 | 1993-04-20 | New York Blood Center, Inc. | Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers |
| US4722840A (en) | 1984-09-12 | 1988-02-02 | Chiron Corporation | Hybrid particle immunogens |
| US4959314A (en) | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
| BR8707471A (pt) | 1986-09-22 | 1988-09-13 | Univ Emory | Vacina e processo de preparacao |
| US5143726A (en) | 1986-12-09 | 1992-09-01 | The Scripps Research Institute | T cell epitopes of the hepatitis B virus nucleocapsid protein |
| GB8903313D0 (en) | 1989-02-14 | 1989-04-05 | Wellcome Found | Conjugates |
| GB8913737D0 (en) | 1989-06-15 | 1989-08-02 | Univ Birmingham | A novel anti-allergy treatment |
| US5178882A (en) | 1990-06-22 | 1993-01-12 | The Regents Of The University Of California | Viral decoy vaccine |
| US5334394A (en) | 1990-06-22 | 1994-08-02 | The Regents Of The University Of California | Human immunodeficiency virus decoy |
| US5142726A (en) * | 1991-04-03 | 1992-09-01 | Mann Robert F | Adjustable bristle length toothbrush |
| GB9114003D0 (en) | 1991-06-28 | 1991-08-14 | Mastico Robert A | Chimaeric protein |
| ZA934199B (en) | 1992-06-18 | 1994-01-10 | Akzo Nv | Carrier system against gnrh |
| US6004763A (en) | 1992-09-11 | 1999-12-21 | Institut Pasteur | Antigen-carrying microparticles and their use in the induction of humoral or cellular responses |
| WO1994009155A1 (en) * | 1992-10-13 | 1994-04-28 | Duke University | Methods of detecting alzheimer's disease |
| JPH08505625A (ja) | 1993-01-11 | 1996-06-18 | ダナ−ファーバー キャンサー インスティチュート | 細胞毒性ｔリンパ球応答の誘導 |
| US6180771B1 (en) | 1993-12-08 | 2001-01-30 | Immulogic Pharmaceutical Corp. | Nucleic acids encoding a house dust mite allergen, Der p III, and uses therefor |
| US5935821A (en) | 1995-01-17 | 1999-08-10 | Board Of Trustees Of The University Of Kentucky | Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma |
| JPH09202735A (ja) | 1996-01-25 | 1997-08-05 | Nof Corp | リポソーム型アレルギー治療薬 |
| US5786161A (en) | 1996-06-06 | 1998-07-28 | Miltenyi Biotec. Gmbh | Isolation and characterization of allergen-binding cells for diagnosis of hypersensitivity |
| SE9604815D0 (sv) | 1996-12-20 | 1996-12-20 | Pharmacia & Upjohn Ab | A metod of diagnosis |
| WO1998040100A1 (en) | 1997-03-10 | 1998-09-17 | Ottawa Civic Loeb Research Institute | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT |
| US8173127B2 (en) | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
| AU743827B2 (en) | 1997-04-09 | 2002-02-07 | Intellect Neurosciences, Inc. | Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof |
| US6169175B1 (en) | 1997-08-06 | 2001-01-02 | Centers For Disease Control And Prevention | Preparation and use of recombinant influenza A virus M2 construct vaccines |
| US6054312A (en) | 1997-08-29 | 2000-04-25 | Selective Genetics, Inc. | Receptor-mediated gene delivery using bacteriophage vectors |
| US6905686B1 (en) * | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| JP2002511385A (ja) | 1997-12-03 | 2002-04-16 | ニューララブ リミテッド | アルツハイマー病におけるβ−アミロイド関連変化を抑制する方法 |
| ES2207177T3 (es) | 1998-02-12 | 2004-05-16 | Apovia, Inc. | Proteinas nucleo de la hepatitis b estrategicamente modificas y sus derivados. |
| US5990085A (en) | 1998-05-04 | 1999-11-23 | Michigan State University | Inhibin-HBc fusion protein |
| EP1123114B1 (en) | 1998-10-21 | 2005-12-28 | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Virus-like particles for the induction of autoantibodies |
| US6380364B1 (en) | 1998-11-23 | 2002-04-30 | Loyola University Of Chicago | Chimeric biotin-binding papillomavirus protein |
| CN100534529C (zh) | 1998-11-30 | 2009-09-02 | 希托斯生物技术股份公司 | 抗原的有序分子呈递，制备及使用的方法 |
| IL143475A0 (en) | 1998-12-04 | 2002-04-21 | Biogen Inc | Hepatitis b virus core antigen particles and vaccines and pharmaceutical compositions containing the same |
| IL145025A0 (en) | 1999-02-25 | 2002-06-30 | Smithkline Beecham Biolog | Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses |
| US20020052311A1 (en) | 1999-09-03 | 2002-05-02 | Beka Solomon | Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders |
| CA2349434A1 (en) | 1999-09-03 | 2001-03-15 | Ramot University Authority For Applied Research & Industrial Development Ltd. | Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases |
| WO2001053457A2 (en) | 2000-01-21 | 2001-07-26 | University Of Connecticut Health Center | Vaccines against neurodegenerative disorders |
| US20030086938A1 (en) | 2000-02-21 | 2003-05-08 | Jensen Martin Roland | Novel methods for down-regulation of amyloid |
| CA2407897A1 (en) | 2000-05-05 | 2001-11-15 | Cytos Biotechnology Ag | Molecular antigen arrays and vaccines |
| US8519005B2 (en) * | 2000-07-27 | 2013-08-27 | Thomas N. Thomas | Compositions and methods to prevent toxicity of antiinflammatory agents and enhance their efficacy |
| US7320793B2 (en) * | 2001-01-19 | 2008-01-22 | Cytos Biotechnology Ag | Molecular antigen array |
| US7094409B2 (en) | 2001-01-19 | 2006-08-22 | Cytos Biotechnology Ag | Antigen arrays for treatment of allergic eosinophilic diseases |
| US7128911B2 (en) | 2001-01-19 | 2006-10-31 | Cytos Biotechnology Ag | Antigen arrays for treatment of bone disease |
| MY144532A (en) * | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
| WO2003024480A2 (en) | 2001-09-14 | 2003-03-27 | Cytos Biotechnology Ag | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
| US7115266B2 (en) | 2001-10-05 | 2006-10-03 | Cytos Biotechnology Ag | Angiotensin peptide-carrier conjugates and uses thereof |
| US20030219459A1 (en) | 2002-01-18 | 2003-11-27 | Cytos Biotechnology Ag | Prion protein carrier-conjugates |
| EP2351770A1 (en) | 2002-07-17 | 2011-08-03 | Cytos Biotechnology AG | Molecular antigen arrays using a virus like particle derived from the ap205 coat protein |
| CN100518823C (zh) | 2002-07-18 | 2009-07-29 | 赛托斯生物技术公司 | 半抗原-载体偶联物及其用途 |
| US20040076645A1 (en) | 2002-07-19 | 2004-04-22 | Bachmann Martin F. | Ghrelin-carrier conjugates |
| MXPA05000819A (es) * | 2002-07-19 | 2005-08-29 | Cytos Biotechnology Ag | Composiciones de vacunas que contienen arreglos de antigeno amiloide beta 1-6. |
| AU2003254914A1 (en) | 2002-08-12 | 2004-03-03 | Kyowa Hakko Kogyo Co., Ltd. | Amino acid-containing chewable |
| TW200509968A (en) * | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
| TW200501962A (en) * | 2003-04-01 | 2005-01-16 | Novartis Ag | Use of carbamazepine derivatives for the treatment of agitation in dementia patients |
| GB0424563D0 (en) * | 2004-11-05 | 2004-12-08 | Novartis Ag | Organic compounds |
-
2004
- 2004-11-05 GB GB0424563A patent/GB0424563D0/en not_active Ceased
-
2005
- 2005-10-28 MY MYPI20055090A patent/MY148584A/en unknown
- 2005-10-28 GT GT200500313A patent/GT200500313A/es unknown
- 2005-11-03 US US11/718,665 patent/US7867499B2/en not_active Expired - Fee Related
- 2005-11-03 EP EP05801760A patent/EP1812050A1/en not_active Withdrawn
- 2005-11-03 CA CA002581300A patent/CA2581300A1/en not_active Abandoned
- 2005-11-03 EP EP20100177232 patent/EP2286830A3/en not_active Withdrawn
- 2005-11-03 BR BRPI0517682-4A patent/BRPI0517682A/pt not_active IP Right Cessation
- 2005-11-03 MX MX2007005430A patent/MX2007005430A/es active IP Right Grant
- 2005-11-03 AR ARP050104609A patent/AR054092A1/es unknown
- 2005-11-03 JP JP2007536128A patent/JP2008515954A/ja not_active Withdrawn
- 2005-11-03 SG SG200907306-5A patent/SG170646A1/en unknown
- 2005-11-03 CN CNA2005800368845A patent/CN101048174A/zh active Pending
- 2005-11-03 WO PCT/EP2005/011788 patent/WO2006048295A1/en not_active Ceased
- 2005-11-03 PE PE2005001290A patent/PE20061047A1/es not_active Application Discontinuation
- 2005-11-03 NZ NZ583688A patent/NZ583688A/en not_active IP Right Cessation
- 2005-11-03 AU AU2005300692A patent/AU2005300692A1/en not_active Abandoned
- 2005-11-03 RU RU2007120689/15A patent/RU2415677C2/ru not_active IP Right Cessation
- 2005-11-03 KR KR1020077010214A patent/KR20070073882A/ko not_active Ceased
- 2005-11-04 TW TW094138839A patent/TWI380825B/zh not_active IP Right Cessation
-
2007
- 2007-03-22 ZA ZA200702369A patent/ZA200702369B/xx unknown
- 2007-04-19 IL IL182692A patent/IL182692A/en not_active IP Right Cessation
- 2007-04-24 EC EC2007007415A patent/ECSP077415A/es unknown
- 2007-05-04 TN TNP2007000166A patent/TNSN07166A1/fr unknown
- 2007-05-14 MA MA29899A patent/MA29020B1/fr unknown
- 2007-05-30 NO NO20072743A patent/NO20072743L/no not_active Application Discontinuation
-
2010
- 2010-02-04 AU AU2010200410A patent/AU2010200410B2/en not_active Ceased
- 2010-12-17 US US12/971,534 patent/US8460676B2/en not_active Expired - Fee Related
-
2011
- 2011-05-02 JP JP2011102847A patent/JP2011157395A/ja active Pending
-
2013
- 2013-05-13 US US13/892,552 patent/US8617566B2/en not_active Expired - Fee Related
- 2013-11-20 US US14/085,048 patent/US20140079730A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0511900A (pt) | composições farmacêuticas | |
| DE602005012035D1 (de) | Kontrast-Verstärkung | |
| CY2014039I1 (el) | Φαρμακευτικες συνθεσεις που περιεχουν λουρασιδονη | |
| DK1991563T3 (da) | Peptidsekvenser og sammensætninger | |
| DK1587478T3 (da) | Farmaceutisk sammensætning | |
| DK1725218T3 (da) | Farmaceutisk sammensætning omfattende pimobendan | |
| DE602005015131D1 (de) | Interleukin-15-antagonistisches peptid | |
| IL184609A0 (en) | Compositions containing an antigen and an adjuvent peptide | |
| MA29020B1 (fr) | Composition contenant une vlp et un peptide amyloide beta | |
| DE602004030951D1 (de) | Rückseitendünnung von bild-array-einrichtungen | |
| DE602005017191D1 (de) | Geruchsreduzierte waschstück-zusammensetzung | |
| DK1794180T3 (da) | Peptidningslutning | |
| EP1875902A4 (en) | MEDIUM SUSPENSIONING EFFECT AND THIS CONTAINING MOISTURIZING FRUIT COMPOSITION | |
| DK1709082T3 (da) | Sammensætning til behandling af patologi knyttet til MSRV/HERV-W | |
| FR2881342B1 (fr) | Composition demaquillante | |
| DE602005023720D1 (de) | Acrylelastomerzusammensetzung | |
| ITMI20042232A1 (it) | Composizione farmaceutica contenente clozapina | |
| BRPI0810057A2 (pt) | Composição farmacêutica contendo floroglucinol e paracetamol | |
| EP1852411A4 (en) | TRIFLUORO NAPHTHALIN DERIVATIVE AND LIQUID CRYSTAL COMPOSITION CONTAINING THE COMPOUND | |
| FR2871686B1 (fr) | Composition anti-decoloration | |
| EP1736488A4 (en) | FLUORPOLYMER CONTAINING STAIN REMOVER | |
| DK1784174T3 (da) | Famaceutisk sammensætning omfattende gabapentin | |
| FI20050753L (fi) | Uudet peptidit | |
| ITMI20040943A1 (it) | Composizione farmaceutica cicatrizzante | |
| DK1787653T3 (da) | Antitumoral farmaceutisk sammensætning indeholdende polypeptidfragmenter af serralysiner |